233 related articles for article (PubMed ID: 31259160)
1. In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment.
Telatin V; Nicoli F; Frasson C; Menegotto N; Barbaro F; Castelli E; Erne E; Palù G; Caputo A
Front Cell Infect Microbiol; 2019; 9():190. PubMed ID: 31259160
[TBL] [Abstract][Full Text] [Related]
2. The effects of direct-acting antiviral agents on the frequency of myeloid-derived suppressor cells and natural killer cells in patients with chronic hepatitis C.
Li Y; Zeng Y; Zeng G; Li J; Zhang X; Cai Q; Chen Y; Lin CS
J Med Virol; 2019 Feb; 91(2):278-286. PubMed ID: 30171691
[TBL] [Abstract][Full Text] [Related]
3. Naïve CD4+ T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+ Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons.
Auma AWN; Shive CL; Lange A; Damjanovska S; Kowal C; Zebrowski E; Pandiyan P; Wilson B; Kalayjian RC; Canaday DH; Anthony DD
Front Immunol; 2021; 12():641230. PubMed ID: 33912168
[TBL] [Abstract][Full Text] [Related]
4. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
5. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
6. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
[TBL] [Abstract][Full Text] [Related]
7. Peripheral PD-1
Romani S; Stafford K; Nelson A; Bagchi S; Kottilil S; Poonia B
Front Immunol; 2019; 10():1470. PubMed ID: 31316516
[TBL] [Abstract][Full Text] [Related]
8. Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers.
Hutchinson JA; Weigand K; Adenugba A; Kronenberg K; Haarer J; Zeman F; Riquelme P; Hornung M; Ahrens N; Schlitt HJ; Geissler EK; Werner JM
Front Immunol; 2018; 9():146. PubMed ID: 29467758
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
[TBL] [Abstract][Full Text] [Related]
10. Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma.
Hetta HF; Zahran AM; Mansor SG; Abdel-Malek MO; Mekky MA; Abbas WA
J Med Virol; 2019 Jul; 91(7):1319-1328. PubMed ID: 30761547
[TBL] [Abstract][Full Text] [Related]
11. Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection.
Auma AWN; Shive CL; Kostadinova L; Anthony DD
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062255
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Changes in Ex Vivo T-Cell Function After Viral Clearance in Chronic HCV Infection.
Han JW; Sung PS; Kim KH; Hong SH; Shin EC; Jun Song M; Park SH
J Infect Dis; 2019 Sep; 220(8):1290-1301. PubMed ID: 31152667
[TBL] [Abstract][Full Text] [Related]
13. Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8
Vranjkovic A; Deonarine F; Kaka S; Angel JB; Cooper CL; Crawley AM
Front Immunol; 2019; 10():1926. PubMed ID: 31456810
[TBL] [Abstract][Full Text] [Related]
14. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
Burchill MA; Golden-Mason L; Wind-Rotolo M; Rosen HR
J Viral Hepat; 2015 Dec; 22(12):983-91. PubMed ID: 26482547
[TBL] [Abstract][Full Text] [Related]
15. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
Pillai V; Lee WM; Thiele DL; Karandikar NJ
J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
[TBL] [Abstract][Full Text] [Related]
16. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
Han JW; Sung PS; Hong SH; Lee H; Koh JY; Lee H; White S; Maslow JN; Weiner DB; Park SH; Jeong M; Heo J; Ahn SH; Shin EC
J Hepatol; 2020 Jul; 73(1):72-83. PubMed ID: 32088322
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8(+) T cells in chronic hepatitis C patients.
Zeng QL; Yang B; Sun HQ; Feng GH; Jin L; Zou ZS; Zhang Z; Zhang JY; Wang FS
Mol Cells; 2014 Jan; 37(1):66-73. PubMed ID: 24552712
[TBL] [Abstract][Full Text] [Related]
18. Effect of Direct Acting Antivirals (DAAs) on Myeloid-Derived Suppressor Cells Population in Egyptian Chronic Hepatitis C Virus Patients: A Potential Immunomodulatory Role of DAAs.
Abdulsamad B; Afifi M; Awaad AK; Elbendary W; Mustafa H; Elsherbini B
Viral Immunol; 2023 May; 36(4):259-267. PubMed ID: 36802279
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Myeloid-Derived Suppressor Cells in Human Immunodeficiency Virus-1/ Hepatitis C Virus-coinfected Patients.
Lei AH; Yang Q; Cai WP; Liu YF; Lan Y; Qin AP; Hu FY; Zhou J
Scand J Immunol; 2016 Jun; 83(6):438-44. PubMed ID: 26972443
[TBL] [Abstract][Full Text] [Related]
20. IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS.
Salem ML; Zidan AA; Attia M; El-Naggar RE; Nassef M; Abou El-Azm AR; El-Bate H; Yussif M; Galal S; Abo Senna M; El Demellawy M
Immunopharmacol Immunotoxicol; 2017 Aug; 39(4):188-198. PubMed ID: 28472907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
